<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14931">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00240526</url>
  </required_header>
  <id_info>
    <org_study_id>100450</org_study_id>
    <nct_id>NCT00240526</nct_id>
  </id_info>
  <brief_title>LT F-up Study 16-20 Yrs After Vaccine Dose of Hepatitis B With/Without HBIg in Newborns to HBeAg+ Mothers</brief_title>
  <official_title>Long-Term Follow-up Study at Years 16, 17, 18, 19 and 20, to Evaluate the Persistence of Immune Response of GlaxoSmithKline Biologicals' Hepatitis B Vaccine Administered With or Without HBIG in Newborns of HBeAg+ Mothers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Thailand: Ministry of Public Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the persistence of anti-HBs antibodies up to 16, 17, 18, 19 and 20 years after
      administration of the first dose of the study vaccine. The Protocol Posting has been updated
      in order to comply with the FDA Amendment Act, Sep 2007.

      No additional subjects will be recruited during this long-term follow-up study and no
      vaccine will be administered.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary study was to evaluate the reactogenicity, immunogenicity and protective efficacy
      of a hepatitis B vaccine in healthy neonates of HBeAg positive mothers if administered with
      or without a dose of HBIg at birth. The current study describes the long term follow up of
      these subjects between Y16 and 20 after primary vaccination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration</measure>
    <time_frame>Years 15, 16, 17, 18, 19 and 20</time_frame>
    <safety_issue>No</safety_issue>
    <description>Concentrations given as GMC expressed as milli-international unit per millilitre (mIU/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Above Pre-defined Cut-off Values</measure>
    <time_frame>Years 15, 16, 17, 18, 19 and 20</time_frame>
    <safety_issue>No</safety_issue>
    <description>Anti-hepatitis B surface antigen (anti-HBs) antibody cut-off values assessed include 1.0 and 10 mIU/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Positive Results for Serological Markers for Hepatitis B Infection</measure>
    <time_frame>Years 15, 16, 17, 18, 19 and 20</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serological markers for hepatitis B infection assessed are hepatitis B surface antigen (HBsAg), antibodies to hepatitis B core antigen (anti-HBc), hepatitis B e antigen (HBeAg) and antibodies to hepatitis B e antigen (anti-HBe).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Different Hepatitis B Infection Statuses</measure>
    <time_frame>Over the entire follow up period (Final assessment of clinical significance was analyzed after the Year 20 time point)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Categories hepatitis B (HB) infection:
Chronic infection: HBsAg and anti-HBc pos (pos) in more than two consecutive samples
False positive: single HB marker (HBsAg, HBeAg, anti-HBc) pos + all other markers negative (neg) in one sample. Consecutive time points all neg.
Possible subclinical breakthrough infection: One or more HB markers pos in one or more consecutive samples.
Isolated natural booster: &gt;4-fold increase of anti-HBs concentrations if &lt;100 mIU/mL at previous sample OR &gt;2- fold increase of anti-HBs concentrations if &gt;=100 mIU/mL at previous sample + other markers neg</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Engerix 4D + HBIg Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Engerix 3D + HBIg Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Engerix 4D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Engerix 3D Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Engerix™ -B</intervention_name>
    <description>3 (Groups A and C) or 4 (Groups B and D) intramuscular injections during the primary study</description>
    <arm_group_label>Engerix 4D</arm_group_label>
    <arm_group_label>Engerix 3D + HBIg Group</arm_group_label>
    <arm_group_label>Engerix 3D Group</arm_group_label>
    <arm_group_label>Engerix 4D + HBIg Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepatitis B immunoglobulin (HBIg)</intervention_name>
    <description>1 intramuscular injections at birth (primary study)</description>
    <arm_group_label>Engerix 3D + HBIg Group</arm_group_label>
    <arm_group_label>Engerix 4D + HBIg Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who had received at least one dose of the study vaccine in the primary study

          -  Written informed consent obtained from each subject before each blood sampling visit

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Poovorawan Y, Chongsrisawat V, Theamboonlers A, Srinivasa K, Hutagalung Y, Bock HL, Hoet B. Long-term benefit of hepatitis B vaccination among children in Thailand with transient hepatitis B virus infection who were born to hepatitis B surface antigen-positive mothers. J Infect Dis. 2009 Jul 1;200(1):33-8. doi: 10.1086/599331.</citation>
    <PMID>19473096</PMID>
  </reference>
  <verification_date>February 2011</verification_date>
  <lastchanged_date>February 17, 2011</lastchanged_date>
  <firstreceived_date>October 13, 2005</firstreceived_date>
  <firstreceived_results_date>June 14, 2010</firstreceived_results_date>
  <responsible_party>
    <name_title>Cheri Hudson; Clinical Disclosure Advisor</name_title>
    <organization>GSK Clinical Disclosure</organization>
  </responsible_party>
  <keyword>Hepatitis B immunoglobulin</keyword>
  <keyword>Hepatitis B antibody persistence</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The baseline characteristics are given for the Year 15 time point. Therefore the number of participants in the Engerix-3D Group is 21, as in the Year 15 participant flow data.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Engerix 4D + HBIg Group</title>
          <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
        </group>
        <group group_id="P2">
          <title>Engerix 3D + HBIg Group</title>
          <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
        </group>
        <group group_id="P3">
          <title>Engerix 4D</title>
          <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60.</description>
        </group>
        <group group_id="P4">
          <title>Engerix 3D Group</title>
          <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Year 15</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19">Number of subjects who come back at Year 15 (Month 180) time-point</participants>
                <participants group_id="P2" count="19">Number of subjects who come back at Year 15 (Month 180) time-point</participants>
                <participants group_id="P3" count="14">Number of subjects who come back at Year 15 (Month 180) time-point</participants>
                <participants group_id="P4" count="21">Number of subjects who come back at Year 15 (Month 180) time-point</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Year 16</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17">Number of subjects who come back at Year 16 (Month 192) time-point</participants>
                <participants group_id="P2" count="19">Number of subjects who come back at Year 16 (Month 192) time-point</participants>
                <participants group_id="P3" count="16">Number of subjects who come back at Year 16 (Month 192) time-point</participants>
                <participants group_id="P4" count="22">Number of subjects who come back at Year 16 (Month 192) time-point</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Year 17</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19">Number of subjects who come back at Year 17 (Month 204) time-point</participants>
                <participants group_id="P2" count="17">Number of subjects who come back at Year 17 (Month 204) time-point</participants>
                <participants group_id="P3" count="13">Number of subjects who come back at Year 17 (Month 204) time-point</participants>
                <participants group_id="P4" count="20">Number of subjects who come back at Year 17 (Month 204) time-point</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Year 18</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16">Number of subjects who come back at Year 18 (Month 216) time-point</participants>
                <participants group_id="P2" count="17">Number of subjects who come back at Year 18 (Month 216) time-point</participants>
                <participants group_id="P3" count="14">Number of subjects who come back at Year 18 (Month 216) time-point</participants>
                <participants group_id="P4" count="20">Number of subjects who come back at Year 18 (Month 216) time-point</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Year 19</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17">Number of subjects who come back at Year 19 (Month 228) time-point</participants>
                <participants group_id="P2" count="16">Number of subjects who come back at Year 19 (Month 228) time-point</participants>
                <participants group_id="P3" count="12">Number of subjects who come back at Year 19 (Month 228) time-point</participants>
                <participants group_id="P4" count="18">Number of subjects who come back at Year 19 (Month 228) time-point</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Year 20</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19">Number of subjects who come back at Year 20 (Month 240) time-point</participants>
                <participants group_id="P2" count="17">Number of subjects who come back at Year 20 (Month 240) time-point</participants>
                <participants group_id="P3" count="13">Number of subjects who come back at Year 20 (Month 240) time-point</participants>
                <participants group_id="P4" count="20">Number of subjects who come back at Year 20 (Month 240) time-point</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Engerix 4D + HBIg Group</title>
          <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
        </group>
        <group group_id="B2">
          <title>Engerix 3D + HBIg Group</title>
          <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
        </group>
        <group group_id="B3">
          <title>Engerix 4D</title>
          <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60.</description>
        </group>
        <group group_id="B4">
          <title>Engerix 3D Group</title>
          <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="19"/>
                <measurement group_id="B3" value="14"/>
                <measurement group_id="B4" value="21"/>
                <measurement group_id="B5" value="73"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Data are given for the Year 15 time point.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="14.5" spread="0.51"/>
                <measurement group_id="B2" value="14.7" spread="0.45"/>
                <measurement group_id="B3" value="14.6" spread="0.50"/>
                <measurement group_id="B4" value="14.5" spread="0.51"/>
                <measurement group_id="B5" value="14.6" spread="0.49"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="6"/>
                <measurement group_id="B4" value="10"/>
                <measurement group_id="B5" value="35"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="8"/>
                <measurement group_id="B4" value="11"/>
                <measurement group_id="B5" value="38"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration</title>
        <description>Concentrations given as GMC expressed as milli-international unit per millilitre (mIU/mL).</description>
        <time_frame>Years 15, 16, 17, 18, 19 and 20</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on subjects from the Long Term According-to-Protocol (LT ATP) cohort for immunogenicity on subjects with available data at the specified time-points</population>
        <group_list>
          <group group_id="O1">
            <title>Engerix 4D + HBIg Group</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
          </group>
          <group group_id="O2">
            <title>Engerix 3D + HBIg Group</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
          </group>
          <group group_id="O3">
            <title>Engerix 4D</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60.</description>
          </group>
          <group group_id="O4">
            <title>Engerix 3D Group</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="15"/>
                  <measurement group_id="O3" value="12"/>
                  <measurement group_id="O4" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration</title>
            <description>Concentrations given as GMC expressed as milli-international unit per millilitre (mIU/mL).</description>
            <units>mIU/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Year 15 (N=17;15;12;17)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="118.6" lower_limit="53.4" upper_limit="263.1"/>
                  <measurement group_id="O2" value="14.8" lower_limit="6.8" upper_limit="32.0"/>
                  <measurement group_id="O3" value="142.8" lower_limit="30.4" upper_limit="669.4"/>
                  <measurement group_id="O4" value="24.2" lower_limit="10.0" upper_limit="58.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 16 (N=15;13;12;16)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="119.3" lower_limit="50.0" upper_limit="284.7"/>
                  <measurement group_id="O2" value="14.1" lower_limit="6.8" upper_limit="29.4"/>
                  <measurement group_id="O3" value="134.3" lower_limit="30.1" upper_limit="599.8"/>
                  <measurement group_id="O4" value="22.9" lower_limit="9.7" upper_limit="54.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 17 (N=17;13;11;13)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="140.0" lower_limit="67.2" upper_limit="291.9"/>
                  <measurement group_id="O2" value="8.2" lower_limit="3.9" upper_limit="17.1"/>
                  <measurement group_id="O3" value="70.2" lower_limit="14.3" upper_limit="344.1"/>
                  <measurement group_id="O4" value="17.0" lower_limit="6.7" upper_limit="43.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 18 (N=14;14;10;13)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="82.3" lower_limit="32.1" upper_limit="211.3"/>
                  <measurement group_id="O2" value="10.8" lower_limit="6.5" upper_limit="17.9"/>
                  <measurement group_id="O3" value="56.5" lower_limit="11.7" upper_limit="271.8"/>
                  <measurement group_id="O4" value="26.1" lower_limit="10.7" upper_limit="63.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 19 (N=13;12;8;11)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="103.3" lower_limit="38.9" upper_limit="274.7"/>
                  <measurement group_id="O2" value="9.5" lower_limit="4.0" upper_limit="22.8"/>
                  <measurement group_id="O3" value="84.9" lower_limit="12.0" upper_limit="600.2"/>
                  <measurement group_id="O4" value="19.9" lower_limit="7.4" upper_limit="53.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 20 (N=13;13;6;12)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="73.9" lower_limit="26.6" upper_limit="205.4"/>
                  <measurement group_id="O2" value="14.3" lower_limit="6.7" upper_limit="30.6"/>
                  <measurement group_id="O3" value="297.1" lower_limit="46.0" upper_limit="1919.5"/>
                  <measurement group_id="O4" value="16.3" lower_limit="7.2" upper_limit="36.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Above Pre-defined Cut-off Values</title>
        <description>Anti-hepatitis B surface antigen (anti-HBs) antibody cut-off values assessed include 1.0 and 10 mIU/mL.</description>
        <time_frame>Years 15, 16, 17, 18, 19 and 20</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on subjects from the Long Term According-to-Protocol (LT ATP) cohort for immunogenicity on subjects with available data at the specified time-points</population>
        <group_list>
          <group group_id="O1">
            <title>Engerix 4D + HBIg Group</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
          </group>
          <group group_id="O2">
            <title>Engerix 3D + HBIg Group</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
          </group>
          <group group_id="O3">
            <title>Engerix 4D</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60.</description>
          </group>
          <group group_id="O4">
            <title>Engerix 3D Group</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="15"/>
                  <measurement group_id="O3" value="12"/>
                  <measurement group_id="O4" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Above Pre-defined Cut-off Values</title>
            <description>Anti-hepatitis B surface antigen (anti-HBs) antibody cut-off values assessed include 1.0 and 10 mIU/mL.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Year 15 (≥ 1.0 mIU/mL) (N=17;15;12;17)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="10"/>
                  <measurement group_id="O4" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 15 (≥ 10 mIU/mL) (N=17;15;12;17)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="9"/>
                  <measurement group_id="O4" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 16 (≥ 1.0 mIU/mL) (N=15;13;12;16)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="12"/>
                  <measurement group_id="O4" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 16 (≥ 10 mIU/mL) (N=15;13;12;16)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="10"/>
                  <measurement group_id="O4" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 17 (≥ 1.0 mIU/mL) (N=17;13;11;13)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="11"/>
                  <measurement group_id="O4" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 17 (≥ 10 mIU/mL) (N=17;13;11;13)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="9"/>
                  <measurement group_id="O4" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 18 (≥ 1.0 mIU/mL) (N=14;14;10;13)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="10"/>
                  <measurement group_id="O4" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 18 (≥ 10 mIU/mL) (N=14;14;10;13)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 19 (≥ 1.0 mIU/mL) (N=14;12;8;11)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 19 (≥ 10 mIU/mL) (N=14;12;8;11)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 20 (≥ 1.0 mIU/mL) (N=13;13;6;12)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 20 (≥ 10 mIU/mL) (N=13;13;6;12)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Positive Results for Serological Markers for Hepatitis B Infection</title>
        <description>Serological markers for hepatitis B infection assessed are hepatitis B surface antigen (HBsAg), antibodies to hepatitis B core antigen (anti-HBc), hepatitis B e antigen (HBeAg) and antibodies to hepatitis B e antigen (anti-HBe).</description>
        <time_frame>Years 15, 16, 17, 18, 19 and 20</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Long Term Total Cohort (LT total cohort) on subjects with available data for the specified marker.</population>
        <group_list>
          <group group_id="O1">
            <title>Engerix 4D + HBIg Group</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
          </group>
          <group group_id="O2">
            <title>Engerix 3D + HBIg Group</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
          </group>
          <group group_id="O3">
            <title>Engerix 4D</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60.</description>
          </group>
          <group group_id="O4">
            <title>Engerix 3D Group</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="19"/>
                  <measurement group_id="O3" value="16"/>
                  <measurement group_id="O4" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Positive Results for Serological Markers for Hepatitis B Infection</title>
            <description>Serological markers for hepatitis B infection assessed are hepatitis B surface antigen (HBsAg), antibodies to hepatitis B core antigen (anti-HBc), hepatitis B e antigen (HBeAg) and antibodies to hepatitis B e antigen (anti-HBe).</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Year 15 HBsAg (N=19;19;14;21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 15 Anti-HBc (N=19;19;14;21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 15 HBeAg (N=4;7;1;8)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 15 Anti-HBe (N=4;7;1;8)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 16 HBsAg (N=16;17;16;22)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 16 Anti-HBc (N=16;17;16;22)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 16 HBeAg (N=6;5;3;11)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 16 Anti-HBe (N=6;5;3;11)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 17 HBsAg (N=19;17;13;19)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 17 Anti-HBc (N=19;17;13;20)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 17 HBeAg (N=9;5;4;10)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 17 Anti-HBe (N=9;5;4;10)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 18 HBsAg (N=16;17;14;20)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 18 Anti-HBc (N=16;17;14;20)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 18 HBeAg (N=8;7;4;10)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 18 Anti-HBe (N=8;7;4;10)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 19 HBsAg (N=17;16;12;18)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 19 Anti-HBc (N=17;16;12;18)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 19 HBeAg (N=8;7;5;10)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 19 Anti-HBe (N=8;7;5;10)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 20 HBsAg (N=19;17;12;20)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 20 Anti-HBc (N=19;17;12;20)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 20 HBeAg (N=8;7;6;14)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 20 Anti-HBe (N=10;9;6;15)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Different Hepatitis B Infection Statuses</title>
        <description>Categories hepatitis B (HB) infection:
Chronic infection: HBsAg and anti-HBc pos (pos) in more than two consecutive samples
False positive: single HB marker (HBsAg, HBeAg, anti-HBc) pos + all other markers negative (neg) in one sample. Consecutive time points all neg.
Possible subclinical breakthrough infection: One or more HB markers pos in one or more consecutive samples.
Isolated natural booster: &gt;4-fold increase of anti-HBs concentrations if &lt;100 mIU/mL at previous sample OR &gt;2- fold increase of anti-HBs concentrations if &gt;=100 mIU/mL at previous sample + other markers neg</description>
        <time_frame>Over the entire follow up period (Final assessment of clinical significance was analyzed after the Year 20 time point)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Long Term Total Cohort (LT total cohort). The maximum amount of subjects who have participated in any of the time points in this study has been given as number of participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Engerix 4D + HBIg Group</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
          </group>
          <group group_id="O2">
            <title>Engerix 3D + HBIg Group</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
          </group>
          <group group_id="O3">
            <title>Engerix 4D</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60.</description>
          </group>
          <group group_id="O4">
            <title>Engerix 3D Group</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="19"/>
                  <measurement group_id="O3" value="16"/>
                  <measurement group_id="O4" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Different Hepatitis B Infection Statuses</title>
            <description>Categories hepatitis B (HB) infection:
Chronic infection: HBsAg and anti-HBc pos (pos) in more than two consecutive samples
False positive: single HB marker (HBsAg, HBeAg, anti-HBc) pos + all other markers negative (neg) in one sample. Consecutive time points all neg.
Possible subclinical breakthrough infection: One or more HB markers pos in one or more consecutive samples.
Isolated natural booster: &gt;4-fold increase of anti-HBs concentrations if &lt;100 mIU/mL at previous sample OR &gt;2- fold increase of anti-HBs concentrations if &gt;=100 mIU/mL at previous sample + other markers neg</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Chronic HB infection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>False positive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="9"/>
                  <measurement group_id="O4" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Possible subclinical breakthrough HB infection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="12"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Isolated natural booster</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="9"/>
                  <measurement group_id="O4" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>As no adverse events data were collected during this study the number of participants at risk is 0 for all groups.</desc>
      <group_list>
        <group group_id="E1">
          <title>Engerix 4D + HBIg Group</title>
          <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
        </group>
        <group group_id="E2">
          <title>Engerix 3D + HBIg Group</title>
          <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
        </group>
        <group group_id="E3">
          <title>Engerix 4D</title>
          <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60.</description>
        </group>
        <group group_id="E4">
          <title>Engerix 3D Group</title>
          <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No safety data were collected during the long-term follow-up study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
